Suzhou Taolue Biotechnology

Suzhou Taolue Biopharmaceutical is a clinical-stage biotechnology company dedicated to the discovery and development of innovative small molecule targeted therapies, primarily for oncology. Founded by experienced drug discovery professionals, the company focuses on addressing clinical resistance in cancer treatment through the design of next-generation kinase inhibitors. Its pipeline features several candidates targeting ROS1, ALK, NTRK, and EGFR mutations, with lead programs currently in Phase 2 clinical trials. Taolue Biopharma operates out of the Suzhou Industrial Park and has secured significant venture capital funding to advance its precision medicine portfolio. The company emphasizes the development of drugs with high blood-brain barrier permeability to treat brain metastases.